PE20211342A1 - Acido ribonucleico (arn) que codifica para una proteina - Google Patents

Acido ribonucleico (arn) que codifica para una proteina

Info

Publication number
PE20211342A1
PE20211342A1 PE2021000874A PE2021000874A PE20211342A1 PE 20211342 A1 PE20211342 A1 PE 20211342A1 PE 2021000874 A PE2021000874 A PE 2021000874A PE 2021000874 A PE2021000874 A PE 2021000874A PE 20211342 A1 PE20211342 A1 PE 20211342A1
Authority
PE
Peru
Prior art keywords
protein
rna
coding
ribonucleic acid
mrna
Prior art date
Application number
PE2021000874A
Other languages
English (en)
Inventor
Justin Antony Selvaraj
Herve Schaffhauser
Friedrich Metzger
Original Assignee
Versameb Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versameb Ag filed Critical Versameb Ag
Publication of PE20211342A1 publication Critical patent/PE20211342A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a un ARNm que comprende una secuencia de acido nucleico que codifica para una proteina y un peptido senal y una unidad de transcripcion, un vector de expresion o un vector de terapia genica que comprende un acido nucleico que codifica para una proteina y un peptido senal. Tambien se describe en la presente una composicion terapeutica que comprende dicho ARNm, unidad de transcripcion, vector de expresion o vector de terapia genica y el uso de la composicion terapeutica en el tratamiento de una enfermedad o una condicion
PE2021000874A 2018-12-19 2019-12-18 Acido ribonucleico (arn) que codifica para una proteina PE20211342A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18214221 2018-12-19
EP19208066 2019-11-08
PCT/EP2019/086019 WO2020127532A2 (en) 2018-12-19 2019-12-18 Rna encoding a protein

Publications (1)

Publication Number Publication Date
PE20211342A1 true PE20211342A1 (es) 2021-07-26

Family

ID=68848313

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000874A PE20211342A1 (es) 2018-12-19 2019-12-18 Acido ribonucleico (arn) que codifica para una proteina

Country Status (18)

Country Link
US (1) US20220002364A1 (es)
EP (1) EP3898982A2 (es)
JP (1) JP2022514863A (es)
KR (1) KR20210105382A (es)
CN (1) CN113454227A (es)
AU (1) AU2019407921A1 (es)
BR (1) BR112021011771A2 (es)
CA (1) CA3120638A1 (es)
CL (1) CL2021001571A1 (es)
CO (1) CO2021007916A2 (es)
IL (1) IL284035A (es)
MA (1) MA54503A (es)
MX (1) MX2021007241A (es)
PE (1) PE20211342A1 (es)
PH (1) PH12021551135A1 (es)
SG (1) SG11202105267VA (es)
TW (1) TW202043477A (es)
WO (1) WO2020127532A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021400488A1 (en) 2020-12-14 2023-06-22 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
JP2024504414A (ja) * 2021-01-26 2024-01-31 シギロン セラピューティクス， インコーポレイテッド 抗原特異的免疫寛容を誘導するための組成物、デバイス及び方法
WO2022187277A1 (en) * 2021-03-01 2022-09-09 The Johns Hopkins University Molecular indexing of proteins by self assembly (mipsa) for efficient proteomic investigations
WO2022216944A1 (en) * 2021-04-07 2022-10-13 Mayo Foundation For Medical Education And Research Methods and materials for reversing atherogenic plaque instability
JP2024515184A (ja) * 2021-04-19 2024-04-05 ヴェルサメブ アーゲー 下部尿路症状の治療方法
CN117813380A (zh) * 2021-06-23 2024-04-02 维萨梅布有限公司 用于调节诸基因表达的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1604688B1 (de) 2001-06-05 2010-02-03 CureVac GmbH Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US20090047259A1 (en) * 2005-12-22 2009-02-19 Enrique Lara Methods of Using the Calcineurin A Variant CnA-beta 1
US9567382B2 (en) * 2008-04-15 2017-02-14 Genzyme Corporation Methods to produce rod-derived cone viability factor (RdCVF)
EP2643468B1 (en) * 2010-11-22 2018-07-04 Amicus Therapeutics, Inc. Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
DK2797613T3 (da) * 2011-10-27 2020-03-02 Wellstat Ophthalmics Corp Vektorer, der koder for rod-derived cone viability-faktor
WO2014005219A1 (en) * 2012-07-02 2014-01-09 Iprogen Biotech Inc. Intracellular protein delivery
US10435694B2 (en) * 2014-03-14 2019-10-08 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
WO2015162930A1 (ja) * 2014-04-24 2015-10-29 一般社団法人 医療産業イノベーション機構 タンパク質発現を向上させる方法およびタンパク質発現用組成物
GB201705484D0 (en) * 2017-04-05 2017-05-17 Quethera Ltd Genetic construct

Also Published As

Publication number Publication date
BR112021011771A2 (pt) 2021-08-31
JP2022514863A (ja) 2022-02-16
AU2019407921A1 (en) 2021-06-10
PH12021551135A1 (en) 2022-02-28
CN113454227A (zh) 2021-09-28
MA54503A (fr) 2021-10-27
CA3120638A1 (en) 2020-06-25
WO2020127532A3 (en) 2020-09-17
KR20210105382A (ko) 2021-08-26
CL2021001571A1 (es) 2022-04-18
SG11202105267VA (en) 2021-07-29
TW202043477A (zh) 2020-12-01
CO2021007916A2 (es) 2021-09-20
MX2021007241A (es) 2021-09-23
IL284035A (en) 2021-08-31
US20220002364A1 (en) 2022-01-06
WO2020127532A2 (en) 2020-06-25
EP3898982A2 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
PE20211342A1 (es) Acido ribonucleico (arn) que codifica para una proteina
ES2657737T3 (es) Vector dual para la inhibición del virus de la inmunodeficiencia humana
PE20181156A1 (es) Genes de ataxia de friedreich modificados y vectores para terapia genica
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
CL2018002991A1 (es) Formulaciones de un inhibidor de lsd1.
DOP2018000245A (es) Proteinas de fusion gdf15 y usos de estas
RS53593B1 (en) NUCLEIC ACID INCLUDING OR ENCODING THE HISTONIC STRUCTURE OF HAND-Loop AND POLY (A) SEQUENCES OR POLYADENYLATION SIGNAL TO INCREASE THE EXPRESSION OF SOME CODED PROTEIN
PE20180241A1 (es) Adenovirus oncolitico que codifica una proteina b7
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
CL2019003405A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
CL2008003323A1 (es) Uso de un anticuerpo que se une a cd20 porque sirve para preparar un medicamento para tratar enfermedades autoinmunes; acido nucleico que codifica una proteina cd20 de mono cynomolgus; vector que lo comprende; celula huesped y polipeptido cd20 de mono cynomolgus (div.sol.no.2639-03).
CL2012001380A1 (es) Composición farmacéutica o cosmética que comprende el polipéptido coriolisina l, las proteínas muy ácidas vapi, vapii, vapiii, y una o más moléculas de ácido nucleico que codifican cualquiera de los polipéptidos recién mencionados; ácido nucleico; vector, célula hospedera; método de preparación de dichos polipéptidos; y método cosmético para exfoliar y/o humectar la piel de un animal.
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
CO2022001977A2 (es) Anticuerpos anti-cd96 y sus métodos de uso
PE20191786A1 (es) Anticuerpo monoclonal para pd-l1
PE20230430A1 (es) Composiciones y metodos para modular simultaneamente la expresion de genes
AR114540A1 (es) VARIANTE DE ARNi CONTRA a-SINUCLEÍNA
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
JP2017511133A5 (es)
CL2017003201A1 (es) Variantes de il-37
EP4223304A3 (en) Novel antimicrobial and anti-cancer therapy
CL2020001494A1 (es) Uso de una proteína no estructural de prv para proteger contra la inflamación del músculo esquelético y cardíaco.
EA202191148A1 (ru) Рнк, кодирующая белок
AR121961A1 (es) Inmunoterapia con citocina
DOP2006000117A (es) Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada